

## Jubilant aims at making JUBI-R available to over 1000 hospitals

04 August 2020 | News

**Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug**



Noida headquartered Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited, has launched remdesivir for injection under the brand name 'JUBI-R' in the Indian market at a price of Rs 4,700 per vial of 100 mg (lyophilized injection).

The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. Jubilant's 24 hour help line will enhance access to 'JUBI-R' during these pandemic times, where timely

access to the drug may prove critical to treatment outcomes.

In order to increase accessibility of 'JUBI-R' to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.

"It gives us immense satisfaction to launch 'JUBI-R' as this drug has a potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market and in other countries," stated Mr. Shyam S. Bhartia, Chairman & Managing Director and Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharma Limited. "The Company's ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programs."